Close Menu
July 31, 2019
Sponsored by
Thermo Fisher Scientific

Considerations and Impact of Implementing Targeted NGS in Myeloid Malignancies

GenomeWebinar

Head, Division of Genetics Department of Lab Medicine and Pathology,
Saint John Regional Hospital

This webinar provides a first-hand look at how a molecular laboratory validated and implemented a targeted next-generation sequencing-based myeloid assay to expedite the assessment of myeloid malignancies and assist in the understanding of myeloid cancers.

The most recent version of the World Health Organization classification system for myeloid neoplasms and acute leukemia, published in 2016, added a number of important biomarkers and genetic alterations for the assessment of myeloid malignancies. As the list of relevant molecular markers continues to grow and new targeted therapies are approved, traditional, single-gene approaches for analyzing myeloid malignancies have become laborious and time consuming. Next-generation sequencing has emerged as the optimal solution by enabling comprehensive assessment of all relevant molecular markers in a single NGS run.

In this webinar, Dr. Nancy Carson, Head of the Division of Genetics at the Saint John Regional Hospital, discusses her team’s experiences as one of the first labs in Canada to implement an NGS-based myeloid assay.

Dr. Carson discusses:

  • Unique considerations and applications of NGS in myeloid malignancies
  • Overview of her experience with with analytical validation and implementation of the assay
  • Impact of the implementation of the assay to date through case studies
  • Future directions
Sponsored by

In PLOS this week: Mycobacterium abscessus linked to gastric conditions, placental gene expression changes associated with preterm birth, and more.

The Guardian reports that UK universities are looking into ways to reduce labs' reliance on single-use plastics.

People with certain gene variants tend to not like vegetables, particularly bitter ones, CNN reports.

MIT's Technology Review reports on a company's genetic test that gauges an embryo's susceptibility to certain diseases.

Nov
13
Sponsored by
Agena Bioscience

This webinar will discuss advances in detecting MET and NTRK variants in tumor samples, which can help clinicians determine the appropriate therapy for cancer patients.

Dec
02
Sponsored by
Sophia Genetics

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.  

Dec
04
Sponsored by
BC Platforms

This webinar will discuss what it takes to begin realizing precision medicine in a comprehensive clinical infrastructure, with insights from the Colorado Center for Personalized Medicine (CCPM).